Regulation And Legal
Sumitomo Pharma Revenue Misstatement Claim ¥165bn
Gotham City Research alleges Sumitomo Pharmaceutical misstated FY2025 revenue by up to ¥165 billion, linked to a ¥48 billion dividend from Swiss subsidiary SMPS.
The report claims the dividend was rec
